Insiders · DNTH

Ryan Savitz

EVP, CFO & Cbo at Dianthus Therapeutics, Inc. /DE/ (DNTH) since September 2023

Ryan Savitz has filed 12 insider reports with the SEC since September 2023, as EVP and CFO & Cbo at Dianthus Therapeutics, Inc. /DE/ (DNTH). In the last 12 months Ryan Savitz sold $25.5M of stock on the open market. In the latest filing, on November 12, 2026, Ryan Savitz sold 124,042 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) for $11.2M at an average of $90.52.

Filings
12
Companies
1
Bought on market
None
Sold on market
$26.2M

Companies where Ryan Savitz is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Dianthus Therapeutics, Inc. /DE/ logo
DNTH
Dianthus Therapeutics, Inc. /DE/
EVP, CFO & Cbosince September 20230$26.2M$84.55Nov 12, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Ryan Savitz with

Other insiders at the same companies

Questions about Ryan Savitz

What is Ryan Savitz's role at Dianthus Therapeutics, Inc. /DE/?
Ryan Savitz reports to the SEC as EVP and CFO & Cbo at Dianthus Therapeutics, Inc. /DE/ (DNTH), according to the latest filing on November 12, 2026.
Has Ryan Savitz bought or sold stock recently?
The most recent open-market sale was on November 12, 2026: sold 124,042 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) for $11.2M at an average of $90.52.
How do I get alerts when Ryan Savitz files?
Follow Ryan Savitz on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Ryan Savitz filed 1 time in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Ryan Savitz (SEC CIK 0001992324). Totals count each trade once, skipping amendments whose original is on file, from Sep 14, 2023 on. View on SEC EDGAR · Get this as JSON